METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
1 . A method for maintaining, improving, or lessening the decline of symptoms associated with ALS in a subject in need thereof wherein the symptom is impaired: functionality, respiratory function, bulbar function, speech, muscle strength or any combination thereof, wherein the method comprises administering to the subject a composition comprising a therapeutically acceptable amount of pridopidine or pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the symptom is impairment in speech.
3 . The method of claim 2 , wherein the impairment of speech comprises reduced speaking rate, reduced phonation time, reduced articulation rate, reduced speech intelligibility and reduced articulation precision.
4 . The method of claim 1 , wherein ALS patient's impaired functionality comprises speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, respiratory insufficiency or any combination thereof.
5 . The method of claim 1 , wherein impaired respiratory function is assessed by slow vital capacity (SVC) or forced vital capacity (FVC) or by the ALSFRS-R-Respiratory sub-domain.
6 . The method of claim 1 , wherein maintaining, improving, or lessening the decline in bulbar function is measured by the ALSFRS-R bulbar subdomain (Q1-Q3) score.
7 . The method of claim 1 , wherein said maintaining, improving, or lessening the decline in bulbar function is measured by the CNS-BFS.
8 . The method of claim 1 , wherein ALS patient's impaired bulbar function comprises impaired speech, swallowing or salivation.
9 . The method of claim 1 , wherein the subject has TRICALS Risk Score between >6 and <−2, a disease duration ≤18 months from symptom onset, and a Slow Vital Capacity (SVC) ≥60% of predicted according to GLI-2012 standards.
10 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is effective in maintaining, reducing or lessening the increase in neurofilament light (NfL) protein levels in a human subject afflicted with ALS.
11 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is effective in maintaining, reducing or lessening levels of glial fibrillary acidic protein (GFAP) or YKL-40.
12 . The method of claim 1 , wherein said subject has faster disease progression as measured by the ALSFRS-R pre-baseline slope.
13 . The method of claim 1 , wherein said subject has faster disease progression as measured by the baseline NfL levels, GFAP, YKL-40 or combination thereof.
14 . The method of claim 1 , wherein the method further comprises assessing a biomarker associated with ALS progression or treatment response: wherein the biomarker comprises cardiac Troponin T (cTnT), and wherein the subject has elevated cTnT levels at baseline, demonstrates a longitudinal change in cTnT levels during treatment, or is stratified according to cTnT levels for assessing disease severity or progression rate.
15 . The method of claim 1 , wherein said subject has early ALS with less than 18 months from symptom onset.
16 . The method of claim 1 , wherein said subject has faster disease progression as measured by the ALSFRS-R pre-baseline slope and early with <18 months from symptom onset.
17 . The method of claim 1 , wherein the maintaining, improving, or lessening the decline is measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).
18 . The method of claim 1 , wherein the treatment efficacy is measured by ALSFRS-R Patient-Ranked Order of Function (PROOF), the ALS Assessment Questionnaire-40 (ALSAQ-40), the Communicative Participation Item Bank (CPIB), the EQ-5D-5L including EQ-VAS or combination thereof.
19 . The method of claim 1 , wherein survival is further evaluated through Week 96, with death equivalents defined as tracheostomy or permanent assisted ventilation (>22 hours/day for >7 consecutive days).
20 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is administered daily, twice a week, three times a week or more often than once daily.
21 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is administered orally.
22 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof administered is 10 mg per day to 90 mg per day.
23 . The method of claim 1 , wherein the pridopidine salt is pridopidine hydrochloride.
24 . The method of claim 1 , further comprising administering a second composition to the subject comprising a therapeutically effective amount of a Second compound, wherein the Second compound is riluzole, edaravone, dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid, sodium phenylbutyrate (PB)/tauroursodeoxycholic acid, SLS-005 (Trehalose), DNL343, CNM-Au8 nanocrystalline gold or ABBV-CLS-7262.
25 . The method of claim 23 , wherein the administration of the Second compound precedes the administration of pridopidine or pharmaceutically acceptable salt thereof.
26 . The method of claim 23 , wherein the administration of pridopidine or pharmaceutically acceptable salt thereof precedes the administration of the Second compound.
27 . The method of claim 23 , wherein the pridopidine or pharmaceutically acceptable salt thereof, is administered adjunctively to the Second compound.
28 . The method of claim 23 , wherein the Second compound is administered adjunctively to the pridopidine or pharmaceutically acceptable salt thereof.